サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1152253

ペット用がん治療の世界市場 - 産業規模、シェア、動向、機会、予測：治療法別、動物タイプ別、がんタイプ別、企業別、地域別（2017年～2027年）

Pet Cancer Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Therapy, By Animal Type, By Cancer Type, By Company, and By Region
出版日: | 発行: TechSci Research | ページ情報: 英文 114 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.53円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

ペット用がん治療の世界市場 - 産業規模、シェア、動向、機会、予測：治療法別、動物タイプ別、がんタイプ別、企業別、地域別（2017年～2027年）
出版日: 2022年11月01日
発行: TechSci Research
ページ情報: 英文 114 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

世界のペット用がん治療の市場規模は、予測期間中の2023年～2027年に目覚ましい成長を遂げると予測されています。

市場成長の主要な要因は、ペットの健康に対する意識の高まりと、動物のがん発症率の増加です。また、市場成長を支えるその他の要因として、ペットの所有率・動物飼育数の拡大、診断技術の進歩、研究開発イニシアチブの増大などが挙げられます。さらに、ペットのオンコロジー治療と管理に関連した研究開発活動への多額の投資が、今後数年間で市場企業に有利な機会を提供する見込みです。

当レポートでは、世界のペット用がん治療市場について調査分析し、セグメント別・地域別の市場規模・シェア予測、市場力学、企業プロファイルなど、体系的な情報を提供しています。

目次

第1章 製品概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19が世界のペット用がん治療市場に与える影響

第5章 VOC（顧客の声）

第6章 世界のペット用がん治療市場の展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • 治療法別（手術、放射線療法、化学療法、免疫療法、その他）
    • 動物タイプ別（犬、猫、その他）
    • がんタイプ別（リンパ腫、肥満細胞がん、乳腺・扁平上皮がん、その他）
    • 企業別（2021年）
    • 地域別
  • 市場マップ

第7章 北米のペット用がん治療市場の展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • 治療法別
    • 動物タイプ別
    • がんタイプ別
    • 国別
  • 北米：国別分析
    • 米国
    • メキシコ
    • カナダ

第8章 欧州のペット用がん治療市場の展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • 治療法別
    • 動物タイプ別
    • がんタイプ別
    • 国別
  • 欧州：国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第9章 アジア太平洋のペットがん治療市場の展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • 治療法別
    • 動物タイプ別
    • がんタイプ別
    • 国別
  • アジア太平洋：国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第10章 南米のペット用がん治療市場の展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • 治療法別
    • 動物タイプ別
    • がんタイプ別
    • 国別
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第11章 中東・アフリカのペット用がん治療市場の展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • 治療法別
    • 動物タイプ別
    • がんタイプ別
    • 国別
  • MEA：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • エジプト
    • トルコ

第12章 市場力学

  • 促進要因
  • 課題

第13章 市場の動向と開発

第14章 競合情勢

  • C.H. Boehringer Sohn Ko. KG
  • ELIAS Animal Health, LLC
  • Zoetis Inc.
  • AB Science S.A.
  • Karyopharm Therapeutics, Inc.
  • Vivesto AB
  • Merial Inc.
  • Elanco Animal Health, Inc.
  • Dechra Pharmaceuticals PLC（Anivive Lifesciences）
  • Torigen Pharmaceuticals Inc.

第15章 戦略的提言

目次
Product Code: 12985

The global pet cancer therapeutics market is anticipated to observe an impressive growth during the forecast period, 2023-2027. The major factors include growing consciousness of pet's health and increasing incidences of cancer among animals. Cancer in pets is one of the primary reasons for death, globally. Nowadays, pets have better chances to get diagnosed with cancer due which early adoption of treatment plans are required, which bolster the growth of the market. The other factors supporting the market's growth are rise in pet ownership or animal adoption, advancement in diagnostic techniques and rise in R&D initiatives. Additionally, heavy investments in research and development activities coupled with oncology treatment and management in pets offers lucrative opportunities to the market players in upcoming years.

Increasing Awareness regarding Pet Healthcare and Treatments

The increasing domestication of animals and growing concerns regarding pet health among the people are supporting the market growth. In 2021, number of pet dogs owned worldwide was 471 million. People are becoming more thoughtful about their pet's health and are expending generously on the best available animal therapeutics. Average American yearly spending on pet dogs is estimated to be USD 1201. In addition, growing pet's health awareness programs is augmenting the growth of the market. For instance, the Blue Buffalo Foundation and the Pet Cancer Awareness Program (PCA) are some initiatives which raise awareness and provide information to the pet parents.

Increasing Prevalence of Cancer

The growing prevalence of cancer among pet animals, is a contributing factor for the growth of the market. Cancer is one of the key causes of death in pets, mostly in dogs that are older than 10 years. According to the Veterinary Cancer Society, in 2017, cancer was the foremost cause of death in 47% of dogs, especially those that are over the age of 10, and 32% of cats. Leukemia and lymphoma are very common cancer in cats and certain breeds of elderly dogs. In 2017, Animal Cancer Foundation published a study, which revealed approximately around 25% of all dogs will develop a tumor at some point in their life.

Technological Advancements

Various technological advancements, such as the development of highly targeted and specific cures for animal cancer treatment with minimal side effects, are also supporting the market growth. Increasing R&D initiatives for cancer management is propelling the market growth, as various anti-cancer therapies are launching for veterinary cancer treatment. For instance, in 2017, Jackson Laboratory launched Tallwood Canine Cancer Research Initiative (TCCRI), to generate a biobank of dog tumors for giving insights on cancer cure through research. Also, organizations such as Animal Cancer Foundation, Veterinary Cancer Society, Petco Foundation and PetCure Oncology are doing oncology research such as canine cancer genome project to gain the knowledge related to the genetic makeup of cancer tumors in animals. The foremost focus is on the development of anticancer drugs and improvising their effectiveness and reducing their toxic effects on the pet's body.

Market Segmentation

The global pet cancer therapeutics market is segmented into therapy, animal type, cancer type, and company. Based on therapy, the market is divided into surgery, radiotherapy, chemotherapy, immunotherapy, and others. Based on animal type, the market is divided into canine, feline, and others. Based on cancer type, the market is segmented into lymphoma, mast cell cancer, mammary & squamous cell cancer, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to rising domestication and rise in the occurrence of pet cancers in the country.

Market Players

C.H. Boehringer Sohn Ko. KG, ELIAS Animal Health, LLC, Zoetis Inc., AB Science S.A., Karyopharm Therapeutics, Inc., Vivesto AB, Merial Inc., Elanco Animal Health, Inc., Dechra Pharmaceuticals PLC (Anivive Lifesciences), and Torigen Pharmaceuticals Inc. are some of the leading companies operating in the market.

Report Scope:

In this report, global pet cancer therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Pet Cancer Therapeutics Market, By Therapy:

  • Surgery
  • Radiotherapy
  • Chemotherapy
  • Immunotherapy
  • Others

Pet Cancer Therapeutics Market, By Animal Type:

  • Canine
  • Feline
  • Others

Pet Cancer Therapeutics Market, By Cancer Type:

  • Lymphoma
  • Mast Cell Cancer
  • Mammary & Squamous Cell Cancer
  • Others

Pet Cancer Therapeutics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Europe & CIS
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Pet Cancer Therapeutics Market

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Pet Cancer Therapeutics Market

5. Voice of Customer

6. Global Pet Cancer Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapy (Surgery, Radiotherapy, Chemotherapy, Immunotherapy, Others)
    • 6.2.2. By Animal Type (Canine, Feline, Others)
    • 6.2.3. By Cancer Type (Lymphoma, Mast Cell Cancer, Mammary & Squamous Cell Cancer, Others)
    • 6.2.4. By Company (2021)
    • 6.2.5. By Region
  • 6.3. Market Map

7. North America Pet Cancer Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapy
    • 7.2.2. By Animal Type
    • 7.2.3. By Cancer Type
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Pet Cancer Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapy
        • 7.3.1.2.2. By Animal Type
        • 7.3.1.2.3. By Cancer Type
    • 7.3.2. Mexico Pet Cancer Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapy
        • 7.3.2.2.2. By Animal Type
        • 7.3.2.2.3. By Cancer Type
    • 7.3.3. Canada Pet Cancer Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapy
        • 7.3.3.2.2. By Animal Type
        • 7.3.3.2.3. By Cancer Type

8. Europe Pet Cancer Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapy
    • 8.2.2. By Animal Type
    • 8.2.3. By Cancer Type
    • 8.2.4. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Pet Cancer Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapy
        • 8.3.1.2.2. By Animal Type
        • 8.3.1.2.3. By Cancer Type
    • 8.3.2. Germany Pet Cancer Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapy
        • 8.3.2.2.2. By Animal Type
        • 8.3.2.2.3. By Cancer Type
    • 8.3.3. United Kingdom Pet Cancer Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapy
        • 8.3.3.2.2. By Animal Type
        • 8.3.3.2.3. By Cancer Type
    • 8.3.4. Italy Pet Cancer Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapy
        • 8.3.4.2.2. By Animal Type
        • 8.3.4.2.3. By Cancer Type
    • 8.3.5. Spain Pet Cancer Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapy
        • 8.3.5.2.2. By Animal Type
        • 8.3.5.2.3. By Cancer Type

9. Asia-Pacific Pet Cancer Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapy
    • 9.2.2. By Animal Type
    • 9.2.3. By Cancer Type
    • 9.2.4. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Pet Cancer Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapy
        • 9.3.1.2.2. By Animal Type
        • 9.3.1.2.3. By Cancer Type
    • 9.3.2. India Pet Cancer Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapy
        • 9.3.2.2.2. By Animal Type
        • 9.3.2.2.3. By Cancer Type
    • 9.3.3. Japan Pet Cancer Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapy
        • 9.3.3.2.2. By Animal Type
        • 9.3.3.2.3. By Cancer Type
    • 9.3.4. South Korea Pet Cancer Therapeutics Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Therapy
        • 9.3.4.2.2. By Animal Type
        • 9.3.4.2.3. By Cancer Type
    • 9.3.5. Australia Pet Cancer Therapeutics Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Therapy
        • 9.3.5.2.2. By Animal Type
        • 9.3.5.2.3. By Cancer Type

10. South America Pet Cancer Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapy
    • 10.2.2. By Animal Type
    • 10.2.3. By Cancer Type
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Pet Cancer Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapy
        • 10.3.1.2.2. By Animal Type
        • 10.3.1.2.3. By Cancer Type
    • 10.3.2. Argentina Pet Cancer Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapy
        • 10.3.2.2.2. By Animal Type
        • 10.3.2.2.3. By Cancer Type
    • 10.3.3. Colombia Pet Cancer Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapy
        • 10.3.3.2.2. By Animal Type
        • 10.3.3.2.3. By Cancer Type

11. Middle East and Africa Pet Cancer Therapeutics Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Therapy
    • 11.2.2. By Animal Type
    • 11.2.3. By Cancer Type
    • 11.2.4. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Pet Cancer Therapeutics Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Therapy
        • 11.3.1.2.2. By Animal Type
        • 11.3.1.2.3. By Cancer Type
    • 11.3.2. Saudi Arabia Pet Cancer Therapeutics Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Therapy
        • 11.3.2.2.2. By Animal Type
        • 11.3.2.2.3. By Cancer Type
    • 11.3.3. UAE Pet Cancer Therapeutics Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Therapy
        • 11.3.3.2.2. By Animal Type
        • 11.3.3.2.3. By Cancer Type
    • 11.3.4. Egypt Pet Cancer Therapeutics Market Outlook
      • 11.3.4.1. Market Size & Forecast
        • 11.3.4.1.1. By Value
      • 11.3.4.2. Market Share & Forecast
        • 11.3.4.2.1. By Therapy
        • 11.3.4.2.2. By Animal Type
        • 11.3.4.2.3. By Cancer Type
    • 11.3.5. Turkey Pet Cancer Therapeutics Market Outlook
      • 11.3.5.1. Market Size & Forecast
        • 11.3.5.1.1. By Value
      • 11.3.5.2. Market Share & Forecast
        • 11.3.5.2.1. By Therapy
        • 11.3.5.2.2. By Animal Type
        • 11.3.5.2.3. By Cancer Type

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. C.H. Boehringer Sohn Ko. KG
  • 14.2. ELIAS Animal Health, LLC
  • 14.3. Zoetis Inc.
  • 14.4. AB Science S.A.
  • 14.5. Karyopharm Therapeutics, Inc.
  • 14.6. Vivesto AB
  • 14.7. Merial Inc.
  • 14.8. Elanco Animal Health, Inc.
  • 14.9. Dechra Pharmaceuticals PLC (Anivive Lifesciences)
  • 14.10. Torigen Pharmaceuticals Inc.

15. Strategic Recommendations